SCHEMBL4273501

SCHEMBL4273501

Clc1ccc(Cl)c(Cl)c1.O=P(O)(O)OCl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.58
CA14 Q9ULX7 2/20 0.44
GGPS1 O95749 1/20 0.44
CA1 P00915 1/20 0.44
MMP8 P22894 1/20 0.42
MMP14 P50281 1/20 0.42
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
ALDH1A1 P00352 4/20 0.41
TSHR P16473 3/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP3A4 P08684 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CASP1 P29466 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FDPS P14324 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL28200084 0.83 TP53 (0.64) TP53CA14GGPS1CA1MMP8
SCHEMBL22730 0.76
SCHEMBL8873179 0.76 TP53 (1.00) TP53ALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL29349499 0.76
Formaldehyde SCHEMBL28747804 0.74 TP53 (0.82) TP53ALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL11661765 0.74 TP53 (0.93) TP53FLT1FLT4KDRALDH1A1
Potassium SCHEMBL29653750 0.74 TP53 (0.93) TP53ALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL5318805 0.74 TP53 (0.93) TP53ALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL7641130 0.74 TP53 (0.93) TP53ALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL30433206 0.74 TP53 (0.93) TP53ALDH1A1TSHRHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928475-B1 ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES RIBOSCIENCE LLC (US) 2018-05-23 EP disclosed
US-7608599-B2 Antiviral phosphoramidates ROCHE PALO ALTO LLC (US) 2009-10-27 US disclosed
EP-1928475-A2 ANTIVIRAL PHOSPHORAMIDATES OF 4'-SUBSTITUTED PRONUCLEOTIDES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-11 EP disclosed
US-20070042988-A1 Antiviral phosphoramidates ROCHE PALO ALTO LLC 2007-02-22 US disclosed
WO-2007020193-A2 ANTIVIRAL PHOSPHORAMIDATES OF 4 ' -SUBSTITUTED PRONUCLEOTIDES F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042988-A1 Antiviral phosphoramidates RPP30, RNASE1, ADORA2B TP53 2088/4885CA14 4457/4885GGPS1 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.